Enable Injections

The enFuse, developed and manufactured by Enable Injections, is designed to enable user-administered subcutaneous delivery of high-volume therapeutics outside of a healthcare facility. Biopharma companies collaboratively partner with Enable Injections to differentiate their portfolios with an ultimate development goal of empowering patients to achieve improved outcomes. Enable employees are technology experts focused on an exceptional patient experience in collaboration with our biopharma partners. AtriCure is currently the leading company in the world in the surgical treatment of Atrial Fibrillation. In 2019, Atricure has a market capitalization of over $500 million.